Stock Price
3.02
Daily Change
0.05 1.68%
Monthly
-3.21%
Yearly
106.85%
Q1 Forecast
2.88

Galectin Therapeutics reported $14.62M in Current Liabilities for its fiscal quarter ending in June of 2024.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Gilead Sciences USD 11.81B 485M Dec/2025
Immunic USD 30.08M 2.77M Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Merck USD 28.63B 2.59B Sep/2025